3Augustin A J, Sehmidt-Erfurth U. Verteporfin and intravitreal triamcinolone aeetonide combination therapy for occult ehoroidal neovaseularization in age-related maeular degeneration [ J ]. Am J Ophlhalmo1,2006,141 : 638 - 645.
4Augustin A J, Schmidt-Erfurth U. Verteporfin therapy combined intravitreal triamcinolone in all types of chornidal neovascularization due to age- related macular degeneration [ J ]. Ophthalmology, 2006.113 : 14 - 22.
4Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy
5Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for
6Bressler SB, Pieramici DJ, Koester JM, et al. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to
7Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analy
8Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trial
9Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neov
10Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol, 1998,43:134-146.
6Hayreh SS,Zimmerman MB.Nonnateritic anterior ischemic optic neuropathy:natural history of visual outcome. Ophthalmology,2008,115:298-305.
7Fallah MR,Khosravi K,Hasheman MN,et al.Efficacy of topical bevacizumab for inhibiting rehibiting recurrent pterygium.Curr Eye Res,2010,35 (1):17-22.
8Gillies MC,Simpson JM,Luo W,et al.A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration:one-year results.Arch Ophthlmo1,2003,121:667-673.
